Iradimed (IRMD) Projected to Post Earnings on Thursday

Iradimed (NASDAQ:IRMD - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.43 per share and revenue of $19.33 million for the quarter. Iradimed has set its Q1 2025 guidance at 0.390-0.430 EPS and its FY 2025 guidance at 1.710-1.810 EPS.

Iradimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.05). The firm had revenue of $19.39 million for the quarter, compared to analysts' expectations of $19.09 million. Iradimed had a net margin of 26.26% and a return on equity of 24.12%. On average, analysts expect Iradimed to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Iradimed Price Performance

Shares of IRMD stock traded up $0.68 during mid-day trading on Tuesday, hitting $53.70. 20,064 shares of the stock traded hands, compared to its average volume of 44,310. The stock has a market cap of $682.80 million, a P/E ratio of 35.80 and a beta of 0.82. The stock's fifty day moving average is $52.54 and its two-hundred day moving average is $54.31. Iradimed has a 52-week low of $40.55 and a 52-week high of $63.29.

Iradimed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, March 5th. Shareholders of record on Monday, February 24th were given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 1.27%. This is a positive change from Iradimed's previous quarterly dividend of $0.15. The ex-dividend date was Monday, February 24th. Iradimed's dividend payout ratio is presently 45.33%.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. StockNews.com raised shares of Iradimed from a "buy" rating to a "strong-buy" rating in a research report on Friday. Roth Mkm reaffirmed a "buy" rating and issued a $72.00 price objective (up from $60.00) on shares of Iradimed in a research report on Friday, February 14th.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.